目錄:MedChemExpress LLC>>信號(hào)通路>> Tivozanib | 替沃扎尼 | MedChemExpress (MCE)
| 參考價(jià) | ￥ 715 |
| 參考價(jià) | ￥ 715 |
更新時(shí)間：2024-01-10 11:18:18瀏覽次數(shù)：97評(píng)價(jià)
聯(lián)系我們時(shí)請(qǐng)說(shuō)明是化工儀器網(wǎng)上看到的信息，謝謝!
| CAS | 475108-18-0 | 純度 | 99.37% |
|---|---|---|---|
| 分子量 | 454.86 | 分子式 | C??H??ClN?O? |
| 供貨周期 | 現(xiàn)貨 | 規(guī)格 | 10 mM * 1 mL |
| 貨號(hào) | HY-10977 | 應(yīng)用領(lǐng)域 | 醫(yī)療衛(wèi)生,化工,生物產(chǎn)業(yè),制藥 |
MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)。
CAS No. : 475108-18-0
MCE 國(guó)際站：Tivozanib
產(chǎn)品活性：Tivozanib (AV-951; KRN951) 是一種有效的、選擇性的、具有口服活性的 VEGFR 酪氨酸激酶 抑制劑，對(duì) VEGFR-1、VEGFR-2、VEGFR-3的 IC50 值分別為 0.21、0.16、0.24 nM。Tivozanib 抑制腫瘤組織中的血管生成和血管通透性，并顯示出抗腫瘤活性。Tivozanib 具有研究轉(zhuǎn)移性腎細(xì)胞癌 (RCC) 的潛力。
研究領(lǐng)域：Protein Tyrosine Kinase/RTK
作用靶點(diǎn)：VEGFR
In Vitro: Tivozanib inhibits the phosphorylation of VEGFR-1, VEGFR-2 and VEGFR-3.
In Vivo: Tivozanib (1 mg/kg; p.o.; 14 days) suppresses the development of CNV lesions and leds to a significant regression of established CNV, reducing the affected areas by 67.7%.
相關(guān)產(chǎn)品：Covalent Screening Library Plus | Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | FDA-Approved Drug Library Mini | Bioactive Compound Library Plus | Kinase Inhibitor Library | Protein Tyrosine Kinase Compound Library | FDA-Approved Drug Library | Anti-Cancer Compound Library | Drug Repurposing Compound Library | Covalent Screening Library | Differentiation Inducing Compound Library | Reprogramming Compound Library | Orally Active Compound Library | FDA Approved & Pharmacopeial Drug Library | Anti-Breast Cancer Compound Library | Anti-Lung Cancer Compound Library | Anti-Pancreatic Cancer Compound Library | Anti-Blood Cancer Compound Library | Anti-Obesity Compound Library | Angiogenesis-Related Compound Library | Targeted Diversity Library | Anti-Liver Cancer Compound Library | Anti-Colorectal Cancer Compound Library | EMA-Approved Drug Library | FDA-Approved Anticancer Drug Library | Human Metabolite Library | Anti-Prostate Cancer Compound Library | Anti-Pulmonary Fibrosis Compound Library | Off-patent Drug Library | Membrane Protein-targeted Compound Library | Membrane Receptor-targeted Compound Library | Highly Selective Inhibitors Library | Cytokine Inhibitors Library | Sorafenib | Lenvatinib | Sunitinib | Regorafenib | Nintedanib | Bevacizumab | Semaxinib | Cabozantinib | Ponatinib | Axitinib | Midostaurin | Chloramphenicol | Pazopanib | PD173074 | 5Z-7-Oxozeaenol | Linifanib | Tanshinone IIA | Vandetanib | Foretinib | SU 5402 | Fruquintinib | SPHINX31 | Ripretinib | E3330 | Dovitinib | GW806742X | Sitravatinib
熱門產(chǎn)品線：重組蛋白 | 化合物庫(kù) | 天然產(chǎn)物 | 熒光染料 | PROTAC | 同位素標(biāo)記物
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
(空格分隔,最多3個(gè),單個(gè)標(biāo)簽最多10個(gè)字符)
會(huì)員.png)
3
化工儀器網(wǎng)